The BRI3BP (BRI3-binding protein) antibody targets a protein encoded by the BRI3BP gene, also known as XTP3TPA or TMEM147. BRI3BP interacts with BRI3 (brain protein I3), a transmembrane protein implicated in neuronal development, apoptosis, and neurodegenerative disorders like Alzheimer’s disease. BRI3BP is ubiquitously expressed, with roles in modulating BRI3 stability, subcellular localization, and function. Studies suggest BRI3BP acts as an adaptor protein, linking BRI3 to cellular pathways involved in protein quality control, endoplasmic reticulum (ER) stress responses, and autophagy.
BRI3BP’s interaction with BRI3 may influence amyloid-beta (Aβ) peptide metabolism, a key factor in Alzheimer’s pathology. Dysregulation of BRI3BP expression has been observed in neurodegenerative conditions, cancer, and metabolic diseases, highlighting its potential as a therapeutic or diagnostic target. Antibodies against BRI3BP are critical tools for detecting its expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They enable researchers to study BRI3BP’s tissue distribution, interaction networks, and role in disease mechanisms. Commercial BRI3BP antibodies are typically raised in rabbits or mice, validated for specificity using knockout controls. Ongoing research aims to clarify BRI3BP’s precise molecular functions and its broader implications in cellular homeostasis and disease.